Japan first to approve Novartis' blockbuster hopeful Cosentyx; Bayer, Hospira win FDA nods;

> Japan has approved Novartis' ($NVS) Cosentyx as a treatment for psoriasis and psoriatic arthritis. Release

> The FDA has green-lighted Bayer's Gadavist injection as the first magnetic resonance contrast agent for pediatric patients less than 2 years of age. Release

> The FDA has given Hospira ($HSP) a thumbs-up for its analgesic Dyloject injection, a treatment for pain management. Release

> Angelini will market Ariad's ($ARIA) Iclusig in Eastern Europe. Report

> Pfizer ($PFE) has granted Georgia State $850,000 to partner with Chinese health officials to expand tobacco control efforts in China's major cities. More

> The Asia-Pacific market for Type 2 diabetes treatments will hit $10.5 billion by 2020, GBI Research predicts. Release

And Finally... The Gates Foundation is using art to encourage vaccination. Story (sub. req.)

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.

Weeks after launching a U.S. trial to evaluate IL-6 inhibitor Kevzara for COVID-19, Sanofi and Regeneron have launched a matching study abroad.